We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

65 hedge funds and large institutions have $242M invested in Intellia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

5% more funds holding

Funds holding: 62 → 65 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

20% less capital invested

Capital invested by funds: $302M → $242M (-$59.1M)

Holders
65
Holders Change
+3
Holders Change %
+4.84%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
21
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.6M
2
SM
Sabby Management
Florida
+$2.03M
3
BIT
BlackRock Institutional Trust
California
+$1.29M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$677K
5
PAM
Panagora Asset Management
Massachusetts
+$605K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.13M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.3M
3
EA
Emerald Acquisition
Washington
-$873K
4
GL
GLG LLC
New York
-$730K
5
LCM
Landscape Capital Management
New Jersey
-$582K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$456K +$180K +9,306 +53%
BIM
27
BlackRock Investment Management
Delaware
$440K -$1.28K -66 -0.3%
CCP
28
Clough Capital Partners
Massachusetts
$422K +$480K +24,800 New
Charles Schwab
29
Charles Schwab
California
$409K +$23.7K +1,224 +5%
AllianceBernstein
30
AllianceBernstein
Tennessee
$390K +$50.3K +2,600 +13%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$351K -$20K -1,035 -5%
EA
32
Emerald Acquisition
Washington
$270K -$873K -45,083 -74%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$251K +$1.94K +100 +0.7%
PA
34
Perceptive Advisors
New York
$250K -$6.33K -327 -2%
CS
35
Credit Suisse
Switzerland
$245K +$279K +14,440 New
TA
36
Teachers Advisors
New York
$187K – – –
CAM
37
ClariVest Asset Management
California
$159K +$181K +9,344 New
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$136K +$156K +8,034 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$123K – – –
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$96K +$17K +877 +18%
NFA
41
Nationwide Fund Advisors
Ohio
$77K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$69K +$65.6K +3,391 +529%
AIG
43
American International Group
New York
$68.5K +$116 +6 +0.1%
FMA
44
FNY Managed Accounts
New York
$68.1K +$77.4K +4,000 New
SO
45
STRS Ohio
Ohio
$54K +$17.4K +900 +39%
CLOS
46
Compagnie Lombard Odier SCmA
Switzerland
$51K – – –
Deutsche Bank
47
Deutsche Bank
Germany
$47K -$98.9K -5,111 -64%
Wells Fargo
48
Wells Fargo
California
$41K – – –
BG
49
BlackRock Group
United Kingdom
$37K – – –
TCM
50
Tradewinds Capital Management
Washington
$37K +$41.6K +2,151 New
1
2
3

NTLA Hedge Fund Activity: Q3 2016 in Review

65 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2016, worth a combined $242M — down 20% from $302M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new NTLA positions and 10 closed out — a net gain of 4 holders — while 21 added to existing stakes and 14 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.6M. The largest seller was EcoR1 Capital, cutting an estimated $2.13M.

  • 65 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2016, up from 62 in Q2 2016.
  • Funds reported $242M of Intellia Therapeutics stock for Q3 2016, down 20% quarter-over-quarter.
  • 14 funds opened new Intellia Therapeutics positions in Q3 2016 and 10 closed out, a net change of +4 holders.
  • The largest Intellia Therapeutics buyer in Q3 2016 was Millennium Management, an estimated $2.6M added.
  • The largest Intellia Therapeutics seller in Q3 2016 was EcoR1 Capital, an estimated $2.13M sold.

Based on aggregated 13F filings for Q3 2016.